Business Context and Reporting Period
Company: Aardvark Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Event: The Company updated its corporate presentation for use in meetings with investors and analysts. This presentation is filed as Exhibit 99.1 and is current as of the filing date.
Financial Metrics
This filing is a Current Report on Form 8-K regarding a corporate presentation update. It does not contain audited or unaudited financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material changes to financial performance or operations are reported in this specific document. The only reported event is the dissemination of updated corporate presentation materials.
Guidance, Outlook, and Risks
Management Commentary: The Company disclaims any obligation to update the corporate presentation material in the future.
Outlook: Specific financial guidance or operational outlook is not detailed within the text of this 8-K filing; such information is contained within the attached Exhibit 99.1 (Corporate Presentation), which is not provided in the source text.
Risks: No specific risks or contingencies are enumerated in this filing text.
Key Facts for Investor Verification
- Verify the contents of the attached "Corporate Presentation" (Exhibit 99.1) for updated strategic or financial data, as the 8-K text itself contains no numerical metrics.
- Note the Company's explicit disclaimer that it has no obligation to update the presentation material in the future.
- Confirm the trading symbol (AARD) and exchange (Nasdaq) for the Common Stock.